Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2025-04-25

First treatment against severe thyroid eye disease

View source ↗

Summary

The European Medicines Agency approved Tepezza (teprotumumab) as the first treatment for severe thyroid eye disease, offering significant symptom improvements i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TEPEZZA (teprotumumab)

Snippet

Tepezza significantly improves symptoms for patients with moderate-to-severe TED